Please contact us for more information or to learn if you are eligible to participate.
This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia who have not received previous treatment.
Dr. Jose Cruz
Edgar Lopez Pacheco
National Cancer Institute (NCI)
Type of Trial